sequence,
Sponsors
Ratchadapisek Sompoj Fund, Chulalongkorn University, Bio-innova and Synchron.Co.,Ltd
Conditions
-Bioequivalence study
Bioequivalence
TamsulosinBioequivalence study in healthy volunteersBioequivalence study in healthy volunteers
Bioequivalence
Losartan
Hydrochlorothiazide
Phase 1
A Bioequivalence study of a randomized, open-label, single oral dose, 3-period, 2-treatment, 3-sequence, partial replicate, crossover study of Telmisartan 80 mg tablets relative to Micardis® 80 mg tablets in healthy Thai volunteers under fasting condition
Active, not recruitingTCTR20170516002
Start: 2017-05-11Target: 69Updated: 2026-03-30
A Bioequivalence study of a randomized, open-label, 4-period, 2-treatment, 2-sequence, replicate, crossover study of Losartan 100 mg + Hydrochlorothiazide 25 mg tablets relative to Fortzaar® 100/25 mg tablets in healthy Thai volunteers under fasting condition
Active, not recruitingTCTR20170629005
Start: 2017-09-01Target: 40Updated: 2026-03-30
A Bioequivalence study of a randomized, open-label, fully replicate crossover design with four-period, two-treatment and two-sequence of Tamsulosin Hydrochloride, 0.4 mg prolonged release tablets relative to Harnal OCAS® 0.4 mg tablets in healthy Thai male volunteers under fasting condition
Active, not recruitingTCTR20181204002
Start: 2019-02-01Target: 32Updated: 2026-03-30